MAP2K7 and neoplasm: Although MEKi have primarily been developed for inhibition of oncogenic signaling, recent scientific interest in their immunomodulatory effects when administered systemically has substantially risen due to promising results after targeted inhibition of MEK in combination with immunotherapeutic agents in certain tumor types with high immunogenicity (10).